Auxiliadora Espana-Gomez - Publications

Imbalanced NK cell subpopulations and TIGIT expression limit cetuximab efficacy in colorectal cancer: A promising target for treatment enhancement.

Journal: Clinical and translational medicine

Published: February 04, 2025

Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: August 04, 2023

Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab.

Journal: Cancers

Published: May 23, 2022

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: May 18, 2021

Totally Laparoscopic Tourniquet ALPPS: Technical Standardization by Combining the Pure Hanging Maneuver and the Approach Through the Sugioka Gates.

Journal: Annals of surgical oncology

Published: March 15, 2021

The Combination of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio with Liquid Biopsy Biomarkers Improves Prognosis Prediction in Metastatic Pancreatic Cancer.

Journal: Cancers

Published: February 17, 2021

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.

Journal: ESMO open

Published: July 24, 2020

Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results.

Journal: BMC cancer

Published: November 08, 2019

Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.

Journal: European journal of clinical investigation

Published: May 28, 2015

Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy.

Journal: World journal of surgery

Published: March 28, 2013

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Journal: The oncologist

Published: May 31, 2012

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Journal: PloS one

Published: April 18, 2012